<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title38.html">
                                    Title 38
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/38CFR4.html">Part 4
                                </a><span>&nbsp/&nbsp<span>
                                Sec.  4.79  Schedule of ratings--eye.
                            </h3>
                            <p class="depth0">Diseases of the Eye------------------------------------------------------------------------</p><p class="depth0">Rating------------------------------------------------------------------------6000 Choroidopathy, including uveitis, iritis, cyclitis, and</p><p class="depth0">choroiditis.6001 Keratopathy.6002 Scleritis.6006 Retinopathy or maculopathy.6007 Intraocular hemorrhage.6008 Detachment of retina.6009 Unhealed eye injury.------------------------------------------------------------------------</p><p class="depth0">General Rating Formula for Diagnostic Codes 6000 through 6009------------------------------------------------------------------------</p><p class="depth0">Evaluate on the basis of either visual impairment due to</p><p class="depth0">the particular condition or on incapacitating episodes,</p><p class="depth0">whichever results in a higher evaluation.</p><p class="depth0">With incapacitating episodes having a total duration of           60</p><p class="depth0">at least 6 weeks during the past 12 months..............</p><p class="depth0">With incapacitating episodes having a total duration of           40</p><p class="depth0">at least 4 weeks, but less than 6 weeks, during the past</p><p class="depth0">12 months...............................................</p><p class="depth0">With incapacitating episodes having a total duration of           20</p><p class="depth0">at least 2 weeks, but less than 4 weeks, during the past</p><p class="depth0">12 months...............................................</p><p class="depth0">With incapacitating episodes having a total duration of           10</p><p class="depth0">at least 1 week, but less than 2 weeks, during the past</p><p class="depth0">12 months...............................................Note: For VA purposes, an incapacitating episode is a period</p><p class="depth0">of acute symptoms severe enough to require prescribed bed</p><p class="depth0">rest and treatment by a physician or other healthcare</p><p class="depth0">provider.6010 Tuberculosis of eye:</p><p class="depth0">Active...................................................        100</p><p class="depth0">Inactive: Evaluate under Sec.   4.88c or Sec.   4.89 of</p><p class="depth0">this part, whichever is appropriate.6011 Retinal scars, atrophy, or irregularities:</p><p class="depth0">Localized scars, atrophy, or irregularities of the                10</p><p class="depth0">retina, unilateral or bilateral, that are centrally</p><p class="depth0">located and that result in an irregular, duplicated,</p><p class="depth0">enlarged, or diminished image...........................</p><p class="depth0">Alternatively, evaluate based on visual impairment due to</p><p class="depth0">retinal scars, atrophy, or irregularities, if this would</p><p class="depth0">result in a higher evaluation.6012 Angle-closure glaucoma:</p><p class="depth0">Evaluate on the basis of either visual impairment due to</p><p class="depth0">angle-closure glaucoma or incapacitating episodes,</p><p class="depth0">whichever results in a higher evaluation.</p><p class="depth0">With incapacitating episodes having a total duration of           60</p><p class="depth0">at least 6 weeks during the past 12 months..............</p><p class="depth0">With incapacitating episodes having a total duration of           40</p><p class="depth0">at least 4 weeks, but less than 6 weeks, during the past</p><p class="depth0">12 months...............................................</p><p class="depth0">With incapacitating episodes having a total duration of           20</p><p class="depth0">at least 2 weeks, but less than 4 weeks, during the past</p><p class="depth0">12 months...............................................</p><p class="depth0">Minimum evaluation if continuous medication is required..         10Note: For VA purposes, an incapacitating episode is a period</p><p class="depth0">of acute symptoms severe enough to require prescribed bed</p><p class="depth0">rest and treatment by a physician or other healthcare</p><p class="depth0">provider.6013 Open-angle glaucoma:</p><p class="depth0">Evaluate based on visual impairment due to open-angle</p><p class="depth0">glaucoma.</p><p class="depth0">Minimum evaluation if continuous medication is required..         106014 Malignant neoplasms (eyeball only):</p><p class="depth0">Malignant neoplasm of the eyeball that requires therapy          100</p><p class="depth0">that is comparable to that used for systemic</p><p class="depth0">malignancies, i.e., systemic chemotherapy, X-ray therapy</p><p class="depth0">more extensive than to the area of the eye, or surgery</p><p class="depth0">more extensive than enucleation.........................Note: Continue the 100-percent rating beyond the cessation of</p><p class="depth0">any surgical, X-ray, antineoplastic chemotherapy or other</p><p class="depth0">therapeutic procedure. Six months after discontinuance of</p><p class="depth0">such treatment, the appropriate disability rating will be</p><p class="depth0">determined by mandatory VA examination. Any change in</p><p class="depth0">evaluation based upon that or any subsequent examination</p><p class="depth0">will be subject to the provisions of Sec.   3.105(e) of this</p><p class="depth0">chapter. If there has been no local recurrence or</p><p class="depth0">metastasis, evaluate based on residuals.</p><p class="depth0">Malignant neoplasm of the eyeball that does not require</p><p class="depth0">therapy comparable to that for systemic malignancies:</p><p class="depth0">Separately evaluate visual impairment and nonvisual</p><p class="depth0">impairment, e.g., disfigurement (diagnostic code 7800),</p><p class="depth0">and combine the evaluations.6015 Benign neoplasms (of eyeball and adnexa):</p><p class="depth0">Separately evaluate visual impairment and nonvisual</p><p class="depth0">impairment, e.g., disfigurement (diagnostic code 7800),</p><p class="depth0">and combine the evaluations.6016 Nystagmus, central......................................         106017 Trachomatous conjunctivitis:</p><p class="depth0">Active: Evaluate based on visual impairment, minimum.....         30</p><p class="depth0">Inactive: Evaluate based on residuals, such as visual</p><p class="depth0">impairment and disfigurement (diagnostic code 7800).6018 Chronic conjunctivitis (nontrachomatous):</p><p class="depth0">Active (with objective findings, such as red, thick               10</p><p class="depth0">conjunctivae, mucous secretion, etc.)...................</p><p class="depth0">Inactive: Evaluate based on residuals, such as visual</p><p class="depth0">impairment and disfigurement (diagnostic code 7800).6019 Ptosis, unilateral or bilateral:</p><p class="depth0">Evaluate based on visual impairment or, in the absence of</p><p class="depth0">visual impairment, on disfigurement (diagnostic code</p><p class="depth0">7800).6020 Ectropion:</p><p class="depth0">Bilateral................................................         20</p><p class="depth0">Unilateral...............................................         106021 Entropion:</p><p class="depth0">Bilateral................................................         20</p><p class="depth0">Unilateral...............................................         106022 Lagophthalmos:</p><p class="depth0">Bilateral................................................         20</p><p class="depth0">Unilateral...............................................         106023 Loss of eyebrows, complete, unilateral or bilateral.....         106024 Loss of eyelashes, complete, unilateral or bilateral....         106025 Disorders of the lacrimal apparatus (epiphora,</p><p class="depth0">dacryocystitis, etc.):</p><p class="depth0">Bilateral................................................         20</p><p class="depth0">Unilateral...............................................         106026 Optic neuropathy:</p><p class="depth0">Evaluate based on visual impairment.6027 Cataract of any type:</p><p class="depth0">Preoperative:</p><p class="depth0">Evaluate based on visual impairment.</p><p class="depth0">Postoperative:</p><p class="depth0">If a replacement lens is present (pseudophakia), evaluate</p><p class="depth0">based on visual impairment. If there is no replacement</p><p class="depth0">lens, evaluate based on aphakia.6029 Aphakia or dislocation of crystalline lens:</p><p class="depth0">Evaluate based on visual impairment, and elevate the</p><p class="depth0">resulting level of visual impairment one step.</p><p class="depth0">Minimum (unilateral or bilateral)........................         306030 Paralysis of accommodation (due to neuropathy of the             20</p><p class="depth0">Oculomotor Nerve (cranial nerve III)).6032 Loss of eyelids, partial or complete:</p><p class="depth0">Separately evaluate both visual impairment due to eyelid</p><p class="depth0">loss and nonvisual impairment, e.g., disfigurement</p><p class="depth0">(diagnostic code 7800), and combine the evaluations.6034 Pterygium:</p><p class="depth0">Evaluate based on visual impairment, disfigurement</p><p class="depth0">(diagnostic code 7800), conjunctivitis (diagnostic code</p><p class="depth0">6018), etc., depending on the particular findings.6035 Keratoconus:</p><p class="depth0">Evaluate based on impairment of visual acuity.6036 Status post corneal transplant:</p><p class="depth0">Evaluate based on visual impairment.</p><p class="depth0">Minimum, if there is pain, photophobia, and glare                 10</p><p class="depth0">sensitivity.............................................6037 Pinguecula:</p><p class="depth0">Evaluate based on disfigurement (diagnostic code 7800).------------------------------------------------------------------------</p><p class="depth0">Impairment of Central Visual Acuity------------------------------------------------------------------------6061 Anatomical loss of both eyes \1\........................        1006062 No more than light perception in both eyes \1\..........        1006063 Anatomical loss of one eye: \1\</p><p class="depth0">In the other eye 5/200 (1.5/60)..........................        100</p><p class="depth0">In the other eye 10/200 (3/60)...........................         90</p><p class="depth0">In the other eye 15/200 (4.5/60).........................         80</p><p class="depth0">In the other eye 20/200 (6/60)...........................         70</p><p class="depth0">In the other eye 20/100 (6/30)...........................         60</p><p class="depth0">In the other eye 20/70 (6/21)............................         60</p><p class="depth0">In the other eye 20/50 (6/15)............................         50</p><p class="depth0">In the other eye 20/40 (6/12)............................         406064 No more than light perception in one eye: \1\</p><p class="depth0">In the other eye 5/200 (1.5/60)..........................        100</p><p class="depth0">In the other eye 10/200 (3/60)...........................         90</p><p class="depth0">In the other eye 15/200 (4.5/60).........................         80</p><p class="depth0">In the other eye 20/200 (6/60)...........................         70</p><p class="depth0">In the other eye 20/100 (6/30)...........................         60</p><p class="depth0">In the other eye 20/70 (6/21)............................         50</p><p class="depth0">In the other eye 20/50 (6/15)............................         40</p><p class="depth0">In the other eye 20/40 (6/12)............................         306065 Vision in one eye 5/200 (1.5/60):</p><p class="depth0">In the other eye 5/200 (1.5/60)..........................     \1\100</p><p class="depth0">In the other eye 10/200 (3/60)...........................         90</p><p class="depth0">In the other eye 15/200 (4.5/60).........................         80</p><p class="depth0">In the other eye 20/200 (6/60)...........................         70</p><p class="depth0">In the other eye 20/100 (6/30)...........................         60</p><p class="depth0">In the other eye 20/70 (6/21)............................         50</p><p class="depth0">In the other eye 20/50 (6/15)............................         40</p><p class="depth0">In the other eye 20/40 (6/12)............................         306066 Visual acuity in one eye 10/200 (3/60) or better:Vision in one eye 10/200 (3/60):</p><p class="depth0">In the other eye 10/200 (3/60)...........................         90</p><p class="depth0">In the other eye 15/200 (4.5/60).........................         80</p><p class="depth0">In the other eye 20/200 (6/60)...........................         70</p><p class="depth0">In the other eye 20/100 (6/30)...........................         60</p><p class="depth0">In the other eye 20/70 (6/21)............................         50</p><p class="depth0">In the other eye 20/50 (6/15)............................         40</p><p class="depth0">In the other eye 20/40 (6/12)............................         30Vision in one eye 15/200 (4.5/60):</p><p class="depth0">In the other eye 15/200 (4.5/60).........................         80</p><p class="depth0">In the other eye 20/200 (6/60)...........................         70</p><p class="depth0">In the other eye 20/100 (6/30)...........................         60</p><p class="depth0">In the other eye 20/70 (6/21)............................         40</p><p class="depth0">In the other eye 20/50 (6/15)............................         30</p><p class="depth0">In the other eye 20/40 (6/12)............................         20Vision in one eye 20/200 (6/60):</p><p class="depth0">In the other eye 20/200 (6/60)...........................         70</p><p class="depth0">In the other eye 20/100 (6/30)...........................         60</p><p class="depth0">In the other eye 20/70 (6/21)............................         40</p><p class="depth0">In the other eye 20/50 (6/15)............................         30</p><p class="depth0">In the other eye 20/40 (6/12)............................         20Vision in one eye 20/100 (6/30):</p><p class="depth0">In the other eye 20/100 (6/30)...........................         50</p><p class="depth0">In the other eye 20/70 (6/21)............................         30</p><p class="depth0">In the other eye 20/50 (6/15)............................         20</p><p class="depth0">In the other eye 20/40 (6/12)............................         10Vision in one eye 20/70 (6/21):</p><p class="depth0">In the other eye 20/70 (6/21)............................         30</p><p class="depth0">In the other eye 20/50 (6/15)............................         20</p><p class="depth0">In the other eye 20/40 (6/12)............................         10Vision in one eye 20/50 (6/15):</p><p class="depth0">In the other eye 20/50 (6/15)............................         10</p><p class="depth0">In the other eye 20/40 (6/12)............................         10Vision in one eye 20/40 (6/12):</p><p class="depth0">In the other eye 20/40 (6/12)............................         0------------------------------------------------------------------------\1\ Review for entitlement to special monthly compensation under 38 CFR</p><p class="depth0">3.350.</p><p class="depth0">Ratings for Impairment of Visual Fields------------------------------------------------------------------------</p><p class="depth0">Rating------------------------------------------------------------------------6080 Visual field defects:</p><p class="depth0">Homonymous hemianopsia...................................         30Loss of temporal half of visual field:</p><p class="depth0">Bilateral................................................         30</p><p class="depth0">Unilateral...............................................         10</p><p class="depth0">Or evaluate each affected eye as 20/70 (6/21)............Loss of nasal half of visual field:</p><p class="depth0">Bilateral................................................         10</p><p class="depth0">Unilateral...............................................         10</p><p class="depth0">Or evaluate each affected eye as 20/50 (6/15)............Loss of inferior half of visual field:</p><p class="depth0">Bilateral................................................         30</p><p class="depth0">Unilateral...............................................         10</p><p class="depth0">Or evaluate each affected eye as 20/70 (6/21)............Loss of superior half of visual field:</p><p class="depth0">Bilateral................................................         10</p><p class="depth0">Unilateral...............................................         10</p><p class="depth0">Or evaluate each affected eye as 20/50 (6/15)............</p><p class="depth0">Concentric contraction of visual field:</p><p class="depth0">With remaining field of 5 degrees: \1\</p><p class="depth0">Bilateral................................................        100</p><p class="depth0">Unilateral...............................................         30</p><p class="depth0">Or evaluate each affected eye as 5/200 (1.5/60)..........With remaining field of 6 to 15 degrees:</p><p class="depth0">Bilateral................................................         70</p><p class="depth0">Unilateral...............................................         20</p><p class="depth0">Or evaluate each affected eye as 20/200 (6/60)...........With remaining field of 16 to 30 degrees:</p><p class="depth0">Bilateral................................................         50</p><p class="depth0">Unilateral...............................................         10</p><p class="depth0">Or evaluate each affected eye as 20/100 (6/30)...........With remaining field of 31 to 45 degrees:</p><p class="depth0">Bilateral................................................         30</p><p class="depth0">Unilateral...............................................         10</p><p class="depth0">Or evaluate each affected eye as 20/70 (6/21)............With remaining field of 46 to 60 degrees:</p><p class="depth0">Bilateral................................................         10</p><p class="depth0">Unilateral...............................................         10</p><p class="depth0">Or evaluate each affected eye as 20/50 (6/15)............6081 Scotoma, unilateral:</p><p class="depth0">Minimum, with scotoma affecting at least one-quarter of           10</p><p class="depth0">the visual field (quadrantanopsia) or with centrally</p><p class="depth0">located scotoma of any size.............................</p><p class="depth0">Alternatively, evaluate based on visual impairment due to</p><p class="depth0">scotoma, if that would result in a higher evaluation....------------------------------------------------------------------------\1\ Review for entitlement to special monthly compensation under 38 CFR</p><p class="depth0">3.350.</p><p class="depth0">Ratings for Impairment of Muscle Function------------------------------------------------------------------------</p><p class="depth0">Equivalent visual</p><p class="depth0">Degree of diplopia                         acuity------------------------------------------------------------------------6090 Diplopia (double vision):</p><p class="depth0"><em>(a)</em> Central 20 degrees...........................     5/200 (1.5/60)</p><p class="depth0"><em>(b)</em> 21 degrees to 30 degrees</p><p class="depth0"><em>(1)</em> Down.....................................    15/200 (4.5/60)</p><p class="depth0"><em>(2)</em> Lateral..................................      20/100 (6/30)</p><p class="depth0"><em>(3)</em> Up.......................................       20/70 (6/21)</p><p class="depth0"><em>(c)</em> 31 degrees to 40 degrees</p><p class="depth0"><em>(1)</em> Down.....................................      20/200 (6/60)</p><p class="depth0"><em>(2)</em> Lateral..................................       20/70 (6/21)</p><p class="depth0"><em>(3)</em> Up.......................................       20/40 (6/12)Note: In accordance with 38 CFR 4.31, diplopia that</p><p class="depth0">is occasional or that is correctable with spectacles</p><p class="depth0">is evaluated at 0 percent.6091 Symblepharon:</p><p class="depth0">Evaluate based on visual impairment,</p><p class="depth0">lagophthalmos (diagnostic code 6022),</p><p class="depth0">disfigurement (diagnostic code 7800), etc.,</p><p class="depth0">depending on the particular findings.------------------------------------------------------------------------

(Authority: 38 U.S.C. 1155)
[73 FR 66550, Nov. 10, 2008]


Sec. Sec.  4.80-4.84  [Reserved]</p><p class="depth0">Impairment of Auditory Acuity</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§.
          Code available <a href="https://github.com/anthonygarvan/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5
      </div>
    </div>
  </footer>
  </body>
</html>
